의약품 및 의료기기 복합 제품 시장 : 시장 예측(2026-2032년)

The Drug-Device Combination Products Market is projected to grow by USD 274.61 billion at a CAGR of 8.36% by 2032.

Drug-device combination products sit at the intersection of pharmaceuticals, biologics, medical devices, digital health, and connected care. These products, including prefilled syringes, autoinjectors, drug-eluting stents, medicated patches, inhalers, infusion systems, implantable drug delivery platforms, and companion diagnostic-enabled therapies, are increasingly central to precision medicine and patient-centric treatment models. Their value lies in improving dose accuracy, adherence, safety, usability, and therapeutic outcomes while supporting care delivery beyond traditional clinical settings.

Regulatory agencies classify combination products based on the product's primary mode of action, requiring sponsors to address both drug and device expectations across quality, safety, performance, human factors, clinical evidence, labeling, post-market surveillance, and risk management. Rising use of biologics, self-administered injectables, minimally invasive procedures, and digitally enabled therapies has made drug-device combination product development more complex and strategically important. Industry stakeholders are prioritizing integrated design controls, pharmaceutical quality systems, biocompatibility testing, extractables and leachables assessment, usability engineering, cybersecurity, and lifecycle management to meet evolving global compliance requirements.

Demand drivers include growth in chronic disease management, home-based healthcare, connected drug delivery devices, wearable injectors, smart inhalers, prefilled delivery systems, and implantable therapeutic devices. Across therapeutic areas such as diabetes, oncology, cardiovascular disease, respiratory care, autoimmune disorders, pain management, and neurology, combination products are reshaping how therapies are administered, monitored, and optimized.

Transformative Shifts in the Drug-Device Combination Products Landscape

The drug-device combination products landscape is undergoing a structural shift from product-centric development toward integrated therapeutic ecosystems. Traditional device-assisted drug delivery is being replaced by connected, user-focused platforms that combine formulation science, mechanical engineering, software, sensors, and real-world performance monitoring. This shift is particularly visible in self-injection systems, wearable drug delivery devices, smart inhalers, and digital adherence solutions designed to reduce treatment burden and support decentralized care.

Regulatory expectations are also transforming the sector. Authorities increasingly emphasize early determination of product classification, robust combination product quality systems, device design validation, human factors studies, clinical usability evidence, and post-market risk monitoring. The convergence of pharmaceutical good manufacturing practices with medical device quality management standards is pushing organizations to create cross-functional development teams that include regulatory affairs, clinical development, engineering, pharmacovigilance, human factors, software quality, and supply chain specialists.

Another major shift is the move toward lifecycle-based product strategy. Sponsors are designing platforms that can support multiple drug formulations, enable dose flexibility, reduce administration errors, and generate adherence or performance data. Sustainability is also gaining attention as inhaler propellants, single-use plastics, sharps disposal, and device recyclability come under greater scrutiny. Together, these changes are increasing the strategic importance of combination product governance, risk-based evidence generation, and global regulatory harmonization.

Cumulative Impact of Artificial Intelligence on Combination Products

Artificial intelligence is increasingly influencing the development, manufacturing, regulation, and clinical use of drug-device combination products. In research and development, AI-enabled modeling can support formulation-device compatibility analysis, dose delivery simulations, failure mode evaluation, and optimization of device ergonomics. Machine learning tools are being explored to analyze human factors data, identify patterns in use errors, and improve device instructions, training materials, and patient support programs.

In manufacturing and quality control, AI can enhance process monitoring, predictive maintenance, visual inspection, anomaly detection, and root-cause analysis across highly regulated production environments. For combination products that require tight integration between a drug container closure system and a delivery device, AI-supported analytics can help detect variability in assembly performance, injection force, dose accuracy, seal integrity, and component defects. These capabilities align with broader industry movement toward continuous verification, digital quality management, and data-driven risk control.

AI also has growing relevance in connected drug delivery devices. Smart inhalers, injection platforms, and wearable systems can generate data on timing, dose events, technique, and adherence. When governed appropriately, AI can help transform this data into actionable insights for patients, clinicians, and care teams. However, the cumulative impact of AI depends on validated algorithms, transparent data governance, cybersecurity safeguards, bias mitigation, privacy compliance, and regulatory alignment. For industry leaders, the immediate opportunity is not only automation, but the creation of safer, more personalized, and more measurable therapeutic experiences.

Key Regional Insights for Drug-Device Combination Products

Asia-Pacific is becoming a critical hub for drug-device combination products due to expanding healthcare access, rising chronic disease prevalence, increasing biologics adoption, and strong manufacturing capabilities in countries such as China, India, Japan, South Korea, and Australia. Regional regulators continue to strengthen medical device and pharmaceutical oversight, encouraging sponsors to build clearer evidence packages for usability, quality, and clinical performance. Demand for diabetes care devices, respiratory drug delivery systems, oncology injectables, and home-based treatment technologies is supporting broader adoption of prefilled syringes, autoinjectors, wearable injectors, and connected delivery platforms.

North America remains one of the most advanced regions for combination product development, supported by mature regulatory pathways, high uptake of biologics and specialty medicines, established clinical research infrastructure, and strong demand for self-administration and connected care. The United States has a highly developed framework for product classification, human factors engineering, current good manufacturing practice expectations, and post-market monitoring, while Canada continues to align device and drug oversight with patient safety and quality requirements. The region's emphasis on decentralized care and chronic disease management is strengthening interest in smart injectors, inhalation systems, implantable drug delivery devices, and digital adherence technologies.

Latin America is evolving as access to advanced therapies, biosimilars, and device-enabled treatment options improves across major healthcare systems. Brazil and Mexico are particularly relevant due to their regulatory modernization efforts, hospital infrastructure expansion, and growing chronic disease burden. Adoption is shaped by reimbursement conditions, public procurement priorities, import dependencies, and local registration requirements. Combination products that improve treatment adherence, reduce hospital visits, and simplify administration are gaining attention in diabetes, respiratory care, cardiovascular therapy, and oncology support.

Europe has a sophisticated regulatory environment shaped by medical device regulation, pharmaceutical quality requirements, notified body involvement, and strong pharmacovigilance systems. The region places significant emphasis on clinical evidence, safety, post-market surveillance, usability, and sustainability. Drug-device combination products in Europe are influenced by growing demand for biologic drug delivery, prefilled systems, inhalers, transdermal technologies, and implantable therapeutic devices. Environmental considerations, including inhaler emissions and device waste, are increasingly relevant to product design and procurement decisions.

The Middle East is experiencing rising interest in advanced drug delivery and connected healthcare as governments invest in specialty care, hospital modernization, diabetes management, and digital health infrastructure. Gulf countries are advancing regulatory capabilities and procurement models that favor high-quality, clinically validated technologies. Combination products that enable outpatient care, chronic disease self-management, and improved medication adherence are becoming more important as healthcare systems respond to noncommunicable disease burdens and population health goals.

Africa presents a diverse and developing landscape for drug-device combination products, with adoption influenced by healthcare infrastructure, affordability, supply chain resilience, training needs, and regulatory capacity. Opportunities are most visible in essential drug delivery, respiratory therapy, infectious disease care, maternal health, diabetes management, and injectable medicines where ease of use and stability are essential. Regional progress depends on stronger regulatory harmonization, local distribution networks, healthcare worker training, and product designs suited to varied care environments.

Key Group Insights for Drug-Device Combination Products

ASEAN is gaining importance as healthcare systems expand access to chronic disease treatment, biologics, and device-enabled therapies. Regulatory convergence efforts across Southeast Asia are improving pathways for medical device registration and pharmaceutical oversight, although country-specific requirements remain important. Demand is supported by rising diabetes, respiratory disease, cardiovascular conditions, and growing private healthcare investment, making user-friendly inhalers, prefilled syringes, autoinjectors, and portable infusion systems strategically relevant.

The GCC is advancing combination product adoption through healthcare modernization, digital health investment, and national strategies focused on chronic disease management and specialty care. Countries in the group are building more sophisticated regulatory and procurement systems, with emphasis on quality, international standards, and clinical value. Drug-device combination products that support self-administration, remote monitoring, and outpatient treatment align well with regional healthcare transformation priorities, particularly in diabetes, obesity-related conditions, respiratory care, oncology, and cardiovascular disease.

The European Union represents a highly regulated and evidence-driven environment for combination products, shaped by strict medical device requirements, pharmaceutical standards, clinical evaluation expectations, and post-market surveillance obligations. Developers must address interactions between medicinal product authorization and device conformity assessment, especially for integral drug-device combinations. The EU's focus on patient safety, traceability, real-world evidence, and sustainability is influencing product design, documentation, and lifecycle management strategies.

BRICS countries collectively reflect a broad mix of manufacturing strength, healthcare demand, regulatory evolution, and access challenges. China and India are major drivers due to their scale, local production capabilities, and increasing adoption of advanced drug delivery technologies. Brazil and South Africa highlight the importance of public health access, affordability, and procurement efficiency, while Russia maintains demand for localized and resilient healthcare supply chains. Across BRICS, combination products that balance performance, cost, manufacturability, and regulatory compliance are especially relevant.

The G7 continues to shape global standards for drug-device combination product innovation through advanced regulatory systems, strong clinical research infrastructure, high biologics utilization, and mature pharmacovigilance and device vigilance frameworks. These economies are central to the development of connected drug delivery, smart inhalers, autoinjectors, implantable drug delivery devices, and software-enabled adherence platforms. Their regulatory and reimbursement expectations often influence evidence strategies used in other regions.

NATO member countries include many advanced healthcare systems with strong emphasis on supply chain security, medical readiness, regulatory quality, and interoperability of health technologies. While NATO is not a healthcare regulatory body, member countries' focus on resilience and preparedness has relevance for injectable therapies, emergency-use delivery systems, pain management products, antidote delivery devices, and portable treatment technologies. Combination products that are reliable, easy to train, stable in varied environments, and compatible with secure logistics can support broader health system resilience.

Key Country Insights for Drug-Device Combination Products

The United States is a leading environment for drug-device combination product development due to its structured regulatory classification process, strong biologics pipeline, advanced clinical research ecosystem, and high demand for self-administered therapies. Canada emphasizes safety, quality, bilingual labeling, and evidence-based review processes, with growing use of biologic delivery systems and chronic disease management technologies. Mexico is strengthening regulatory oversight while demand rises for diabetes, respiratory, cardiovascular, and injectable therapies supported by hospital expansion and regional manufacturing connections.

Brazil is a major Latin American environment for advanced drug delivery due to its large public and private healthcare systems, chronic disease burden, and ongoing regulatory modernization. The United Kingdom maintains strong capabilities in clinical research, health technology assessment, digital health, and device-enabled medicines, with particular interest in usability, patient adherence, and care pathway efficiency. Germany is highly influential in Europe due to its medical technology base, strict quality expectations, advanced hospital systems, and demand for biologics, prefilled syringes, infusion systems, and connected care solutions.

France combines robust healthcare coverage, strong pharmacovigilance expectations, and interest in patient-friendly delivery technologies for chronic and specialty diseases. Russia's combination product environment is shaped by localization priorities, supply chain resilience, and demand for injectable and hospital-based therapies. Italy and Spain are important European healthcare systems where aging populations, chronic disease management, and public procurement dynamics influence demand for inhalers, prefilled delivery systems, transdermal products, and infusion technologies.

China is rapidly advancing in drug-device combination products through regulatory reforms, domestic innovation, large-scale manufacturing, and growing adoption of biologics and specialty medicines. India is expanding as both a manufacturing base and a demand center, with relevance in affordable injectable delivery, respiratory devices, biosimilars, and chronic disease care. Japan is characterized by high quality expectations, an aging population, sophisticated device engineering, and strong demand for safe, precise, and user-friendly delivery systems.

Australia has a well-developed regulatory and healthcare environment with interest in home-based care, digital health, and chronic disease management technologies. South Korea is increasingly important due to its advanced medical technology sector, digital health capabilities, biologics manufacturing strength, and demand for connected, high-performance drug delivery platforms. Across these countries, successful strategies depend on aligning product design, regulatory evidence, local usability needs, reimbursement pathways, and supply chain execution.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated development planning from the earliest concept stage, ensuring that drug formulation, device design, software components, packaging, labeling, human factors, and manufacturing requirements are aligned before pivotal development milestones. Early regulatory classification and engagement with relevant authorities can reduce uncertainty, especially when products include digital features, sensors, connectivity, or companion diagnostics.

Organizations should strengthen combination product quality systems by bridging pharmaceutical quality requirements with medical device design controls, risk management, supplier qualification, process validation, complaint handling, and post-market surveillance. Human factors engineering should be treated as a core development discipline rather than a late-stage validation activity, particularly for self-administered, wearable, inhaled, or implantable products.

Leaders should also invest in data governance and cybersecurity for connected drug delivery products. As devices generate adherence and performance data, manufacturers need validated analytics, privacy safeguards, secure software updates, and clear responsibilities across the product lifecycle. Supply chain resilience is equally critical, including dual sourcing of critical components, container closure integrity assurance, and robust monitoring of electronics, polymers, needles, sensors, and sterile components.

Commercial and clinical teams should focus on demonstrable value: reduced administration errors, improved adherence, fewer clinic visits, better patient experience, and measurable therapeutic support. Evidence generation should include usability data, real-world performance insights, patient-reported outcomes, and health system workflow benefits where appropriate. Finally, sustainability should be embedded into product design through material selection, device recyclability, lower-waste packaging, and responsible end-of-life planning.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public-domain and industry-recognized sources relevant to drug-device combination products. The methodology includes review of regulatory guidance, healthcare authority publications, medical device and pharmaceutical quality standards, peer-reviewed literature, clinical practice trends, public health data, and policy documents related to combination product development, drug delivery systems, human factors engineering, connected medical devices, and post-market surveillance.

The analysis prioritizes data-backed insights from recognized regulatory and healthcare institutions, including guidance on product classification, design controls, current good manufacturing practice expectations, biocompatibility, usability engineering, software lifecycle management, cybersecurity, pharmacovigilance, and device vigilance. Regional, group, and country insights are synthesized from documented healthcare infrastructure trends, regulatory developments, chronic disease burden indicators, biologics adoption patterns, digital health initiatives, and medical technology manufacturing capabilities.

No market sizing, market share estimation, revenue forecasting, or speculative numerical projection is included. The research framework emphasizes qualitative evidence, regulatory context, clinical relevance, technology adoption, patient safety, and operational implications. Insights are cross-checked for consistency across multiple source categories to support reliable executive-level interpretation.

Conclusion

Drug-device combination products are becoming essential to modern healthcare as therapies move toward precision dosing, self-administration, connected monitoring, and integrated patient support. The sector's evolution is being shaped by biologics growth, chronic disease management needs, digital health adoption, regulatory rigor, and demand for safer, more convenient treatment experiences.

The most successful stakeholders will be those that manage combination products as unified therapeutic systems rather than separate drug and device components. This requires early regulatory strategy, strong quality integration, human-centered design, validated manufacturing processes, cybersecurity readiness, and lifecycle evidence generation. Regional differences in regulation, infrastructure, reimbursement, and patient access will continue to influence adoption patterns, making localization and compliance planning critical.

Artificial intelligence, connected devices, and real-world data have the potential to improve development efficiency, product reliability, adherence, and clinical decision support. However, their impact depends on responsible validation, transparent governance, and patient trust. As healthcare systems seek better outcomes outside traditional care settings, drug-device combination products will remain a high-priority innovation area for pharmaceutical, medical device, and digital health stakeholders.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug-Device Combination Products Market, by Product Type

• 7.1. Introduction
• 7.2. Drug-Eluting Stents
• 7.3. Inhalers
• 7.4. Injector Systems
  • 7.4.1. Auto-Injectors
  • 7.4.2. Needle-Free Injectors
• 7.5. Prefilled Syringes & Pens
• 7.6. Topical Medicines
• 7.7. Transdermal Patches

8. Drug-Device Combination Products Market, by Technology

• 8.1. Introduction
• 8.2. Advanced Release Technologies
• 8.3. Biodegradable Technology
• 8.4. Conventional Device-Drug Technology
• 8.5. Smart Device Technologies
  • 8.5.1. Automatic Dosing
  • 8.5.2. Digital Monitoring

9. Drug-Device Combination Products Market, by Dosage Form

• 9.1. Introduction
• 9.2. Liquid Dosage Forms
• 9.3. Semi-Solid Dosage Forms
  • 9.3.1. Creams
  • 9.3.2. Ointments
  • 9.3.3. Powders
• 9.4. Solid Dosage Forms
  • 9.4.1. Capsules
  • 9.4.2. Tablets

10. Drug-Device Combination Products Market, by Therapeutic Class

• 10.1. Introduction
• 10.2. Cardiovascular Medications
• 10.3. Diabetes & Endocrinology
• 10.4. Hormonal Replacement Therapy
• 10.5. Oncology Drugs
  • 10.5.1. Chemotherapy
  • 10.5.2. Participatory Oncology Treatment
• 10.6. Pain Management

11. Drug-Device Combination Products Market, by End-User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Homecare Settings
• 11.4. Hospitals and Clinics
• 11.5. Specialty Clinics

12. Drug-Device Combination Products Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Drug-Device Combination Products Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Drug-Device Combination Products Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AbbVie Inc.
• 16.3. B. Braun SE
• 16.4. Baxter International Inc.
• 16.5. Becton, Dickinson and Company
• 16.6. BIOTRONIK SE & Co. KG
• 16.7. Boston Scientific Corporation
• 16.8. Braile Biomedica
• 16.9. Cardinal Health, Inc.
• 16.10. CODAN Companies
• 16.11. Cook Group Incorporated
• 16.12. F. Hoffmann-La Roche Ltd.
• 16.13. Fresenius Kabi
• 16.14. ICU Medical, Inc.
• 16.15. InSitu Technologies Inc.
• 16.16. JMS North America Corporation
• 16.17. Lepu Medical Technology Company
• 16.18. Medtronic PLC
• 16.19. MicroPort Scientific Corporation
• 16.20. Novartis AG
• 16.21. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 16.22. SOOIL Developments Co., Ltd.
• 16.23. Stryker Corporation
• 16.24. Teleflex Incorporated
• 16.25. Terumo Group
• 16.26. Viatris Inc.
• 16.27. W. L. Gore & Associates Inc.